INSM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Insmed Inc (INSM) does not present a strong buying opportunity for a beginner, long-term investor at this time. The technical indicators show bearish momentum, insider selling is significantly increasing, and there are no recent positive news catalysts. While analysts remain optimistic about the company's long-term potential, the current price trend and lack of short-term trading signals suggest holding off on purchasing the stock for now.
The technical indicators for INSM are bearish. The MACD histogram is negative and expanding, RSI is neutral at 24.734, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 139.741. Overall, the technical analysis indicates downward momentum.
The launch of Brinsupri has been well-received by physicians, and the drug is expected to address a large, underserved market with limited competition. Revenue growth in Q4 2025 was strong, increasing by 152.62% YoY.
Insiders are selling shares, with a 167.93% increase in selling activity over the last month. The company reported disappointing Phase 2b trial results for brensocatib, which missed all efficacy endpoints. Technical indicators are bearish, and the stock is underperforming in the short term.
In Q4 2025, the company demonstrated strong revenue growth of 152.62% YoY, reaching $263.84M. However, net income remains negative at -$328.49M, though it improved by 39.46% YoY. EPS also improved to -1.54, up 17.56% YoY. Gross margin increased to 82.51%, showing operational efficiency improvements.
Analysts maintain a positive outlook on INSM, with multiple firms raising price targets recently. Guggenheim raised its target to $230, RBC Capital to $216, and Raymond James initiated coverage with a $200 target. Analysts are optimistic about Brinsupri's growth trajectory and its potential to address a large market. However, some firms have adjusted their models following the negative Phase 2b trial results.
